<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3">Over the last two decades, there were significant advances in understanding MM disease biology and in development of several new drugs that allowed a paradigm shift from a palliative intent towards the active management of the disease aiming to prolong event-free survival (EFS) and overall survival (OS) [
 <xref ref-type="bibr" rid="CR1">1</xref>]. Nowadays, induction followed by autologous stem cell transplantation (ASCT) after high-dose melphalan conditioning continues the standard treatment for MM patients under the age of 65 years [
 <xref ref-type="bibr" rid="CR1">1</xref>, 
 <xref ref-type="bibr" rid="CR5">5</xref>–
 <xref ref-type="bibr" rid="CR7">7</xref>]. Some studies suggest that age at the time of transplant does not have prognostic significance on outcome after ASCT [
 <xref ref-type="bibr" rid="CR8">8</xref>, 
 <xref ref-type="bibr" rid="CR9">9</xref>], but its safety and efficacy remain uncertain for patients over that age [
 <xref ref-type="bibr" rid="CR9">9</xref>–
 <xref ref-type="bibr" rid="CR16">16</xref>].
</p>
